The funding will support the next phase of the company’s global “smart factory” buildout, which includes a manufacturing facility under construction in the Netherlands.
The multi-million-dollar investment expands the CDMO’s sterile manufacturing footprint and is meant to increase capacity to support biologics and advanced therapies.
Go beyond similarity in this webchat with a Thermo Fisher Scientific expert on how a p-value-based multivariate residual approach verifies pharmaceutical raw materials.
